- Home
- PHAR vs SAFT Comparison
PHAR vs SAFT Comparison
Compare PHAR & SAFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- SAFT
- Stock Information
- Founded
- PHAR 1988
- SAFT 1979
- Country
- PHAR Netherlands
- SAFT United States
- Employees
- PHAR N/A
- SAFT 551
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- SAFT Property-Casualty Insurers
- Sector
- PHAR Health Care
- SAFT Finance
- Exchange
- PHAR Nasdaq
- SAFT Nasdaq
- Market Cap
- PHAR 951.7M
- SAFT 1.0B
- IPO Year
- PHAR N/A
- SAFT N/A
- Fundamental
- Price
- PHAR $14.34
- SAFT $69.53
- Analyst Decision
- PHAR Strong Buy
- SAFT
- Analyst Count
- PHAR 3
- SAFT 0
- Target Price
- PHAR $30.00
- SAFT N/A
- AVG Volume (30 Days)
- PHAR 14.9K
- SAFT 72.4K
- Earning Date
- PHAR 10-23-2025
- SAFT 11-04-2025
- Dividend Yield
- PHAR N/A
- SAFT 5.28%
- EPS Growth
- PHAR N/A
- SAFT 65.99
- EPS
- PHAR N/A
- SAFT 5.73
- Revenue
- PHAR $339,836,000.00
- SAFT $1,199,774,000.00
- Revenue This Year
- PHAR $17.44
- SAFT N/A
- Revenue Next Year
- PHAR $8.46
- SAFT N/A
- P/E Ratio
- PHAR N/A
- SAFT $12.21
- Revenue Growth
- PHAR 22.44
- SAFT 16.96
- 52 Week Low
- PHAR $7.31
- SAFT $68.76
- 52 Week High
- PHAR $17.08
- SAFT $90.00
- Technical
- Relative Strength Index (RSI)
- PHAR 50.39
- SAFT 38.58
- Support Level
- PHAR $14.22
- SAFT $69.47
- Resistance Level
- PHAR $16.29
- SAFT $71.59
- Average True Range (ATR)
- PHAR 0.50
- SAFT 1.19
- MACD
- PHAR -0.13
- SAFT -0.14
- Stochastic Oscillator
- PHAR 37.30
- SAFT 21.08
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.